OncoMatch/Clinical Trials/NCT06130579
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Is NCT06130579 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies IFN-Α for myeloid leukemia.
Treatment: IFN-Α — To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: TP53 mutation
Demographics
Prior therapy
Must have received: allogeneic hematopoietic stem cell transplantation
within 2 months after receiving the first allogeneic hematopoietic stem cell transplantation
Lab requirements
Blood counts
absolute neutrophil count (anc) greater than 0.5×10^9/l
Kidney function
creatinine < 1.5mg/dl
Cardiac function
cardiac ejection index >55%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06130579 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received allogeneic hematopoietic stem cell transplantation.
Does this trial require TP53?
Yes, TP53 mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 12 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify